9α-fluoro-11β-17α-diacetoxy-21-methoxy-16α-methylpregna-1,4-diene-3,20-dione | 150587-18-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 9α-fluoro-11β-17α-diacetoxy-21-methoxy-16α-methylpregna-1,4-diene-3,20-dione
• 英文别名: [(8S,9R,10S,11S,13S,14S,16R,17R)-17-acetyloxy-9-fluoro-17-(2-methoxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-11-yl] acetate
• CAS: 150587-18-1
• 化学式: C₂₇H₃₅FO₇
• 分子量: 490.569
• InChiKey: VNQWNNUGVAKDCI-OXJRMJBBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  35
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  96
• 氢给体数：
  0
• 氢受体数：
  8

文献信息

• [EN] ANTI-INFLAMMATORY COMPOUNDS FOR OPHTHALMIC USE<br/>[FR] COMPOSES ANTI-INFLAMMATOIRES DESTINES A UN USAGE OPHTALMIQUE
  申请人：ALCON LABORATORIES, INC.

  公开号：WO1994026769A1

  公开（公告）日：1994-11-24

  (EN) Novel anti-inflammatory compounds, compositions of these compounds and use of such compounds to treat inflammed ocular tissue are described. The compounds are derivatives and analogues of known steroid compounds (e.g., dexamethasone) and are advantageously characterized in that they do not cause any significant increase in intraocular pressure during chronic use.(FR) Nouveaux composés anti-inflammatoires, compositions contenant ces composés et leur utilisation dans le traitement de tissus oculaires enflammés. Ces composés sont des dérivés et des analogues de composés stéroïdiens connus (la dexaméthasone, par exemple), et sont avantageux dans la mesure où ils ne produisent pas d'augmentation notable de la pression intraoculaire lors d'une utilisation chronique.

  （中）本文描述了一些新型的抗炎化合物，这些化合物的组成以及它们的用途，用于治疗炎症眼组织。这些化合物是已知类固醇化合物（例如地塞米松）的衍生物和类似物，其优点在于长期使用时不会引起眼内压力显著增加。
• ANTI-INFLAMMATORY COMPOUNDS FOR OPHTHALMIC USE
  申请人：ALCON LABORATORIES, INC.

  公开号：EP0650496B1

  公开（公告）日：1998-09-16
• NOVEL COMPOSITION
  申请人：Chen Chien-Hung

  公开号：US20110281829A1

  公开（公告）日：2011-11-17

  This disclosure relates to a pharmaceutical composition that includes a first agent selected from the group consisting of an oxidative phosphorylation inhibitor, an ionophore, and an adenosine 5′-monophosphate-activated protein kinase (AMPK) activator; a second agent that possesses anti-inflammatory activity; and a third agent that is a serotonin metabolite.
• NOVEL COMPOSITION FOR TREATING METABOLIC SYNDROME AND OTHER CONDITIONS
  申请人：Chen Chien-Hung

  公开号：US20120183600A1

  公开（公告）日：2012-07-19

  The invention relates to a composition that includes a first agent selected from the group consisting of an oxidative phosphorylation inhibitor, an ionophore, and an adenosine 5′-monophosphate-activated protein kinase (AMPK) activator; a second agent that possesses anti-inflammatory activity; and a third agent that possesses serotonin activity.
• US5223493A
  申请人：——

  公开号：US5223493A

  公开（公告）日：1993-06-29